Abstracts tagged "vasculitis and systemic vasculitides"

Abstract Number: 2625 • 2019 ACR/ARP Annual Meeting
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Gelsomina Alle¹, John Jaramillo Gallego ², Marina Scolnik ³, Valeria Scaglioni ², Martin Brom ⁴, Carlos Varela ⁵, Gustavo Greloni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Nephrology Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study was to evaluate the predictors of advanced chronic kidney disease (ACKD) in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis…
Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Marilia Dagostin¹, Sergio Nunes ², Samuel Shinjo ³ and Rosa Pereira ⁴, ¹University of Sao Paulo, São Paulo, Brazil, ²Univeristy Of Sao Paulo, São Paulo, ³Univeristy Of Sao Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].